Skip to main content
TGTX logo

TG Therapeutics, Inc. (TGTX) Stock: Price, Forecast & Analyst Target

TG Therapeutics, Inc. (TGTX) — MoonshotScore 90/100 (Exceptional band), calculated Nov 18, 2026. Price $64.88 (-1.88%), as of the Nov 19, 2026 trading session; market cap $9.81B. Expected results Feb 25, 2027.

Educational signal · not a buy or sell recommendation · How to read this

Market value / cash and short-term investments: 19.44× (cash as of Sep 30, 2026) · expected results Feb 25, 2027

$64.88 −$1.24 (-1.88%) Market Cap $9.81B

TG Therapeutics, Inc. · TGTX · NASDAQ · Healthcare · Biotechnology

Research dated 2026-09-13 (results through Q2 FY2026; the quarter ended Sep 2026 not covered): TG Therapeutics is a commercial-stage biopharmaceutical company whose reported revenue now comes overwhelmingly from product sales rather than licensing or royalty income. The case depends on whether rising product demand can continue to outrun expanding research and commercial spending while turning uneven cash generation into a durable pattern.

Price as of Nov 19, 2026

Key Statistics

90 of 100

MoonshotScore v2 · TG Therapeutics (TGTX)

Exceptional
Business Quality Elite (91)
Financial Safety Okay (43)
Valuation Rich (33)
Growth Durability Compounding (98)
Momentum Surging (97)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Elite quality and elite growth, but an expensive valuation; the market is already moving on it. Business Quality: Elite; Financial Safety: Okay; Valuation: Rich; Growth Durability: Compounding; Momentum: Surging.

  • EPS beat 2 of the last 8 reports
  • Altman Z 6.34 · Piotroski F 6
  • ROE 17.6% · ROA 6.7% · current ratio 4.50 · earnings yield 1.2% · free-cash-flow yield 0.9%

Holding back: a rich price

Helping: business quality, durable growth, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for TGTX (57 recorded, newest six shown)
RecordedScoreBand
76Strong
93Exceptional
93Exceptional
93Exceptional
90Exceptional
90Exceptional

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$64.88
Change on the day-1.88%
52-week range$26.76–$68.03
Market capitalisation$9.81B—
Price / earnings (trailing)84.19
Shares traded on the day1.66M
Beta (volatility vs the S&P 500)1.81

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 19, 2026: low $28, high $65, latest $65. 4 reported quarters marked, 0 above and 4 below the recorded estimate. 1 other dated event marked. $65 $28 high $65 Feb 26, 2026 · Earnings results · reported below the recorded estimate · close $301May 6, 2026 · Earnings results · reported below the recorded estimate · close $432Aug 3, 2026 · Earnings results · reported below the recorded estimate · close $523Nov 9, 2026 · Earnings call · management outlook · no recorded estimate to compare · close $604Nov 9, 2026 · Earnings results · reported below the recorded estimate · close $605 Oct 17, 2025 Nov 19, 2026 · $65 $35Oct 17, 2025$35Oct 31, 2025$31Nov 14, 2025$33Nov 28, 2025$31Dec 12, 2025$31Dec 26, 2025$28Jan 9, 2026$31Jan 23, 2026$29Feb 6, 2026$30Feb 20, 2026$29Mar 6, 2026$30Mar 20, 2026$34Apr 2, 2026$35Apr 17, 2026$34May 1, 2026$40May 15, 2026$38May 29, 2026$50Jun 12, 2026$56Jun 26, 2026$57Jul 10, 2026$56Jul 24, 2026$50Aug 7, 2026$54Aug 21, 2026$56Sep 4, 2026$57Sep 18, 2026$54Oct 2, 2026$54Oct 16, 2026$61Oct 30, 2026$65Nov 13, 2026

Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.

Events behind the price

  • · Earnings results · below the recorded estimate
  • · Earnings results · below the recorded estimate
  • · Earnings results · below the recorded estimate
  • · Earnings call · management outlook
  • · Earnings results · below the recorded estimate

Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.

Upcoming events

As of

  1. Next results dueProvider estimate

Management outlook

  • Our core business metrics support our increased full year U.S. revenue guidance of $915 million to $920 million and our expectation for a strong fourth quarter and full year 2026.

    Adam Waldman · Statement from

  • On spending, we continue to expect full-year R&D and SG&A expenses, excluding stock-based comp, to be in line with our prior guidance of $450 million-$500 million, inclusive of those subcutaneous BRIUMVI manufacturing and secondary source manufacturer startup activities.

    Sean Power · Statement from

How to read these dates

A statement's date is the earnings call where it was made, not a deadline. Management expectations and estimated dates can change.

Read management statements

Other perspectives

Council score for TG Therapeutics (TGTX): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Strong
Financial Safety Neutral
Valuation Weak
Growth Durability Strong
Momentum Strong

Legends Council

4 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Favorable read

Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Moderate
Margin of Safety Overvalued
Profit Margin Neutral
Revenue Growth Strong
Debt/Equity Negative
ROE Moderate
Gross Margin Strong

Read on: Nov 16, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Nov 16, 2026, the Munger lens read the price at that time as overvalued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is TG Therapeutics (TGTX), and what does it report?

Short answer · as of

TG Therapeutics acquires, develops and markets therapies aimed at autoimmune disorders and B-cell malignancies.

Its portfolio includes ublituximab, a glycoengineered monoclonal antibody, alongside antibody and oral drug candidates directed at immune and cancer targets.

The biotechnology label invites a pipeline-first reading, but the reported business is already product-led. Product revenue accounts for nearly all sales, while royalties, licensing and other revenue remain peripheral; consolidated revenue therefore measures commercial uptake far more than milestone-driven deal activity.

2 · Latest results

What do the latest results show for TG Therapeutics (TGTX)?

Revenue and gross profit reached fresh sequential highs in the latest reported period. Operating profit and net income nevertheless retreated as research spending surged, showing that stronger sales did not translate proportionately into earnings.

Revenue exceeded the prevailing estimate while earnings fell well short of it. Management expects growth to lean toward the closing quarter and says spending reflects continued investment in the commercial organization and direct-to-consumer efforts; that is management’s explanation, while the reported accounts show the immediate mechanism was heavier research expense.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Latest quarter · revenue
$259.94M Sep 30, 2026
Latest quarter · R&D
$51.29M Sep 30, 2026
Latest quarter · SG&A
$80.67M Sep 30, 2026
Latest quarter · FMP standardized operating result
$85.90M Sep 30, 2026
Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026$259.94M$51.29M$80.67M$85.90M
Jun 30, 2026$240.34M$95.34M$82.13M$21.67M
Mar 31, 2026$204.92M$48.40M$88.22M$34.80M
Dec 31, 2025$192.57M$41.19M$62.74M$50.49M
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Did results meet expectations?

Reported earnings and revenue alongside the estimates recorded by the provider.

Latest report · revenue
$259.94M Nov 9, 2026
Latest report · revenue estimate
$245.47M Nov 9, 2026
Latest report · revenue vs estimate
Above estimate Nov 9, 2026
Latest report · EPS vs estimate
Below estimate Nov 9, 2026
Report dateRevenue · reportedRevenue · estimateEPS · reportedEPS · estimate
Nov 9, 2026$259.94M$245.47M$0.3500$0.3593
Aug 3, 2026$240.34M$229.77M$0.0500$0.3057
May 6, 2026$204.92M$200.33M$0.1400$0.2300
Feb 26, 2026$192.57M$191.79M$0.1400$0.3500
How to read these figures

Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Sep 2026$260M$55M$0.35 (diluted)
Q2 FY2026$240M$8M$0.05 (diluted)
Q1 FY2026$205M$20M$0.12 (diluted)
Q4 FY2025$193M$23M$0.14 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for TG Therapeutics (TGTX)?

Short answer

Cash and short-term investments were $504.67M at the Sep 30, 2026 balance-sheet date. Operating cash flow was $45.23M for the quarter ended Sep 30, 2026, meaning operations generated cash. These figures do not establish a cash runway.

Liquidity is substantial relative to recent operating cash use, and short-term solvency ratios indicate ample coverage of near-term obligations. The latest period produced positive operating cash flow after an alternating pattern of inflows and outflows, so cash conversion has improved without yet becoming dependable.

Debt exceeds cash and short-term investments, leaving TG Therapeutics in a net-debt position despite its large liquidity reserve. Earnings quality also warrants attention because a prior quarterly net result stood far above operating profit; the resulting annual profit should not be treated as a clean picture of recurring operations.

The practical risk is expense absorption: gross profit is growing, but research and commercial investment can consume that progress before it reaches operating cash flow. A runway cross-check indicates considerable funding capacity at the recent rate of cash use, yet sustained product growth matters more than the runway calculation because leverage remains material.

Data-derived red flags

  • Inconsistent delivery — missed Wall Street EPS estimates in 6 of the last 8 reported quarters.
  • Rich valuation — a P/E of 84.19 runs well above the Healthcare sector’s ~21.70x, leaving little room for a miss.

How much cash does the business generate or use?

Quarterly operating cash flow shows cash generated or used by operations.

Latest quarter · operating cash flow
$45.23M Sep 30, 2026
Previous quarter · operating cash flow
$39.26M Jun 30, 2026
Period endOperating cash flowCapital expenditure (reported)
Sep 30, 2026$45.23M−$280,000
Jun 30, 2026$39.26M−$290,000
Mar 31, 2026−$17.89M−$50,000
Dec 31, 2025$19.66M−$70,000
How to read these figures

Amounts are in US dollars. Negative operating cash flow means the business used cash. Capital spending is shown as reported; we do not combine it into a free-cash-flow or runway estimate. The bars share one scale.

4 · What to check next?

What should you watch next at TG Therapeutics (TGTX)?

Short answer · as of

The next earnings report is expected on Feb 25, 2027.

Watch whether revenue accelerates into the closing quarter as management expects, and whether gross-profit growth again exceeds the combined pressure from research and commercial spending. The useful confirmation would be concurrent progress in operating profit and operating cash flow, not revenue growth alone.

Consensus forecasts assume continued expansion in revenue and earnings across the available horizon. The nearer test is the scheduled earnings release: another revenue beat paired with an earnings shortfall would reinforce the pattern of successful commercial growth being reinvested faster than it reaches shareholders’ earnings.

What management is planning

Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.

  1. Yeah, I think it's fair to say we'll expect to launch in the second mid-2027.

    Adam Waldman ·

  2. So taken together, all that supports our expectation for a strong fourth quarter and another raise to our full year guidance here.

    Adam Waldman ·

2 more statements are quoted under Upcoming events

5 · Peer comparison

How does TG Therapeutics compare with its peers?

Short answer

TG Therapeutics's score ranks 9th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

TG Therapeutics differs from a development-stage biotechnology company because product sales already dominate revenue and operations are profitable. Its valuation and operating results therefore respond to commercial execution as well as clinical development.

It also differs from a diversified pharmaceutical business: royalties, licensing and other income contribute little beside product revenue, while research spending remains substantial and the portfolio extends across autoimmune disease and B-cell malignancies. That combination creates high gross margins and meaningful operating leverage, but also concentrates the financial story around continued uptake of marketed therapy and disciplined portfolio investment.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Kiniksa Pharmaceuticals, Ltd. (KNSA) Same industry, near in market value$93.53 Nov 19, 2026$7.35B98 5-pillar Nov 18, 2026
Exelixis, Inc. (EXEL) Same industry, near in market value$65.83 Nov 19, 2026$16.1B98 5-pillar Nov 18, 2026
Krystal Biotech, Inc. (KRYS) Named competitor$315.82 Nov 19, 2026$9.36B96 5-pillar Nov 18, 2026
Ascendis Pharma A/S (ASND) Same industry, near in market value$255.96 Nov 19, 2026$16.8B96 5-pillar Nov 18, 2026
Halozyme Therapeutics, Inc. (HALO) Same industry, near in market value$93.04 Nov 19, 2026$10.6B95 5-pillar Nov 18, 2026
Neurocrine Biosciences, Inc. (NBIX) Same industry, near in market value$162.86 Nov 18, 2026$16.5B95 5-pillar Nov 18, 2026
Bio-Techne Corporation (TECH) Same industry, near in market value$72.70 Nov 19, 2026$11.4B92 5-pillar Nov 18, 2026
Corcept Therapeutics Incorporated (CORT) Same industry, near in market value$67.79 Nov 18, 2026$7.42B91 5-pillar Nov 18, 2026
TG Therapeutics (TGTX) — this page$64.88$9.81B90
Protagonist Therapeutics, Inc. (PTGX) Named competitor$127.16 Nov 18, 2026$8.30B88 5-pillar Nov 18, 2026
Ligand Pharmaceuticals Incorporated (LGND) Same industry, near in market value$298.71 Nov 18, 2026$5.98B71 5-pillar Nov 18, 2026
Oruka Therapeutics, Inc. (ORKA) Same industry, near in market value$97.57 Nov 19, 2026$6.62B67 5-pillar Nov 18, 2026
Belite Bio, Inc. (BLTE) Same industry, near in market value$156.23 Nov 18, 2026$6.35B64 5-pillar Nov 18, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$78.00 – $83.00
Consensus target
$80.50
Median target
$80.50

Consensus record · Captured .

Measured against a quoted price of $64.88 (as of Nov 19, 2026).

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Sep 10, 2026

Transactions
9
Identified insiders
5
Purchases
0
Sales
1
Other transactions
8

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Institutional ownership
82.2% Period end Sep 30, 2026
Previous quarter · ownership
79.4% Prior to period end Sep 30, 2026
Reporting holders
482 Period end Sep 30, 2026
Previous quarter · holders
465 Prior to period end Sep 30, 2026
Holders in provider snapshotShares
Blackrock, INC.22,634,933
State Street Corp8,488,874
Vanguard Portfolio Management LLC7,880,546
Vanguard Capital Management LLC6,256,425
Geode Capital Management, LLC3,703,676

Tracked investors

Which of the 16 named investors we follow held TGTX in their latest 13F filing, and what they did against the filing before it.

InvestorManager13F quarterPortfolio weightValueLast quarter
Bridgewater AssociatesFounded by Ray DalioQ3 20260.14%$32.72MAdded +36.5% shares

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Holder snapshot as of Sep 30, 2026. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about TG Therapeutics (TGTX)?

Read these with our analysis →

What Investors Ask About TG Therapeutics (TGTX) — Healthcare

The last 2 questions are answered from this page's own dated data, not from the research.

What role does ublituximab play at TG Therapeutics?

Ublituximab is a glycoengineered monoclonal antibody associated with TG Therapeutics’ work in relapsing multiple sclerosis and B-cell malignancies. It connects the company’s commercial-stage identity with its broader immune and oncology development focus.

Why can TG Therapeutics revenue rise while earnings weaken?

Research expense can rise faster than gross profit, as occurred in the latest reported period. Revenue advanced and selling expense eased, yet heavier research spending reduced operating and net profit.

Are TG Therapeutics product sales producing operating cash?

The latest period generated operating cash, but preceding periods alternated between use and generation. Product-led revenue growth has therefore reached cash flow without establishing consistent conversion.

How does TG Therapeutics commercial spending shape its outlook?

Management is investing in its commercial organization and direct-to-consumer activity while expecting growth to strengthen later in the year. The relevant test is whether that spending produces enough additional product revenue to expand operating profit and cash flow.

What is the TGTX stock price today?

The last price recorded for TG Therapeutics, Inc. (TGTX), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the TGTX price target?

The analyst consensus price target for TG Therapeutics, Inc. (TGTX), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 81 figures on this page — 2 from SEC filings and earnings calls, 71 from Financial Modeling Prep (FMP), 4 with no recorded source, 3 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-13), by section of the research

  • Summary at the top of the page: Business description; Revenue by segment; Annual revenue and net result (USD millions); Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Management outlook — dated call excerpts
  • 1. What is TG Therapeutics (TGTX), and what does it report?: Sector / industry (provider taxonomy); Business description; Revenue by segment; Annual revenue and net result (USD millions)
  • 2. What do the latest results show for TG Therapeutics (TGTX)?: Quarterly income statement (USD thousands); Reported versus estimated, last 8 quarters; Management outlook — dated call excerpts; Most recent periodic reports
  • 3. What are the financial strengths and risks for TG Therapeutics (TGTX)?: Cash, investments and debt; Cash and investment components; Cash and short-term investments over time (USD millions); Operating cash flow by quarter (USD millions); Cash runway cross-check (ours); Cash against market value; Trailing twelve-month ratio set; Distress and quality screens; Quarterly income statement (USD thousands); Annual revenue and net result (USD millions)
  • 4. What should you watch next at TG Therapeutics (TGTX)?: Management outlook — dated call excerpts; Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Reported versus estimated, last 8 quarters; Next earnings report; Analyst revenue and earnings estimates (average); Recent SEC filings
  • 5. How does TG Therapeutics compare with its peers?: Business description; Revenue by segment; Annual revenue and net result (USD millions); Quarterly income statement (USD thousands); Trailing twelve-month ratio set
  • FAQ: What role does ublituximab play at TG Therapeutics?: Business description
  • FAQ: Why can TG Therapeutics revenue rise while earnings weaken?: Quarterly income statement (USD thousands); Reported versus estimated, last 8 quarters
  • FAQ: Are TG Therapeutics product sales producing operating cash?: Revenue by segment; Operating cash flow by quarter (USD millions); Quarterly income statement (USD thousands)
  • FAQ: How does TG Therapeutics commercial spending shape its outlook?: Management outlook — dated call excerpts; Revenue by segment; Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions)
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.